Business Description
Vivani Medical Inc
NAICS : 541714
SIC : 2833
ISIN : US92854B1098
Description
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 1 | |||||
| Debt-to-EBITDA | -0.78 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -24.8 | |||||
| 3-Year EPS without NRI Growth Rate | -21.3 | |||||
| 3-Year FCF Growth Rate | -27.1 | |||||
| 3-Year Book Growth Rate | 90.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.29 | |||||
| 9-Day RSI | 32.13 | |||||
| 14-Day RSI | 39.18 | |||||
| 6-1 Month Momentum % | 72.9 | |||||
| 12-1 Month Momentum % | 66.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.03 | |||||
| Quick Ratio | 4.03 | |||||
| Cash Ratio | 3.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.5 | |||||
| Shareholder Yield % | -16.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -79.15 | |||||
| ROA % | -50.41 | |||||
| ROIC % | -159.64 | |||||
| ROC (Joel Greenblatt) % | -196.8 | |||||
| ROCE % | -60.87 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.95 | |||||
| Price-to-Tangible-Book | 3.95 | |||||
| EV-to-EBIT | -3.32 | |||||
| EV-to-Forward-EBIT | -1.32 | |||||
| EV-to-EBITDA | -3.37 | |||||
| EV-to-FCF | -3.65 | |||||
| Earnings Yield (Greenblatt) % | -30.12 | |||||
| FCF Yield % | -27.6 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers